Pneumococcal polysaccharide vaccine (PPSV23)

Routine vaccination:

• Minimum age: 2 years
• Not recommended for routine use in healthy individuals. Recommended only for the vaccination of persons with certain high-risk conditions.
• Administer PPSV at least 8 weeks after the last dose of PCV to children aged 2 years or older with certain underlying medical conditions like anatomic or functional asplenia (including sickle cell disease), HIV infection, cochlear implant or cerebrospinal fluid leak.
• An additional dose of PPSV should be administered after 5 years to children with anatomic/functional asplenia or an immunocompromising condition.
• PPSV should never be used alone for prevention of pneumococcal diseases amongst high–risk individuals.

Children with medical conditions for which PPSV23 and PCV13 are indicated in the age group 24 through 71 months are as following:

• Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus; cerebrospinal fluid leaks; or cochlear implant.
• Children with anatomic or functional asplenia (including sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction);
• Children with immunocompromising conditions: HIV infection, chronic renal failure and nephrotic syndrome, diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation, congenital immunodeficiency.